Evidence map›Paper›PMID 41962383›Full record

Observational studyBreast (Edinburgh, Scotland)2026

Prevalence of cardiac dysfunction and longitudinal changes in cardiac function after breast cancer treatment with chemotherapy with/without radiation therapy compared with controls.

L T van der Wal, S W M C Maass, M R de Boer, M H Blanker, A P G Crijns, J A Gietema, P van der Meer, G H de Bock, D Brandenbarg

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Breast (Edinburgh, Scotland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

L T van der WalUniversity of Groningen, University Medical Center Groningen, Department of Primary and Long-Term Care, Cure and Care in the Community Context (FOUR-C) research program, Hanzeplein 1, HPC: FA21, PO Box 196, Groningen, 9700 RB, the Netherlands. Electronic address: l.t.van.der.wal@umcg.nl.
S W M C MaassUniversity of Groningen, University Medical Center Groningen, Department of Primary and Long-Term Care, Cure and Care in the Community Context (FOUR-C) research program, Hanzeplein 1, HPC: FA21, PO Box 196, Groningen, 9700 RB, the Netherlands.
M R de BoerUniversity of Groningen, University Medical Center Groningen, Department of Primary and Long-Term Care, Cure and Care in the Community Context (FOUR-C) research program, Hanzeplein 1, HPC: FA21, PO Box 196, Groningen, 9700 RB, the Netherlands.
M H BlankerUniversity of Groningen, University Medical Center Groningen, Department of Primary and Long-Term Care, Cure and Care in the Community Context (FOUR-C) research program, Hanzeplein 1, HPC: FA21, PO Box 196, Groningen, 9700 RB, the Netherlands.
A P G CrijnsUniversity of Groningen, University Medical Center Groningen (UMCG), Department of Radiation Oncology, Hanzeplein 1, P.O. Box 30.001, 9700 RB, Groningen, the Netherlands.
J A GietemaUniversity of Groningen, University Medical Center Groningen (UMCG), Department of Medical Oncology, Hanzeplein 1, PO Box 30.001, Groningen, 9700 RB, the Netherlands.
P van der MeerUniversity of Groningen, University Medical Center Groningen (UMCG), Department of Cardiology, Hanzeplein 1, PO Box 30.001, Groningen, 9700 RB, the Netherlands.
G H de BockUniversity of Groningen, University Medical Center Groningen (UMCG), Department of Epidemiology, Hanzeplein 1, HPC: FA40, PO Box 30.001, Groningen, 9700 RB, the Netherlands.
D BrandenbargUniversity of Groningen, University Medical Center Groningen, Department of Primary and Long-Term Care, Cure and Care in the Community Context (FOUR-C) research program, Hanzeplein 1, HPC: FA21, PO Box 196, Groningen, 9700 RB, the Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionBreast cancer survivors are known to have a higher prevalence of mild systolic cardiac dysfunction compared to the general population, due to the effects of chemotherapy with/without radiation therapy. However, the long-term prevalence of cardiac dysfunction and changes in (dys)function over time, remain unclear. MATERIALS AND

methodsWe added a follow-up measurement to a matched-cohort study. Women were recruited from general practices, and echocardiographic data and medical records from general practices were collected for analysis. The primary outcome was the prevalence of mild left ventricular systolic dysfunction, defined as a left ventricular ejection fraction (LVEF) <54%. Secondary outcomes were diastolic dysfunction, right ventricular dysfunction and longitudinal changes of LVEF over time.

resultsOf the 700 women enrolled in the initial study (T1), 336 (48%) were included in the follow-up (T2). At T2, the median age was 70 years (IQR 65-75) for breast cancer survivors, with a median follow-up time of 19 years (IQR 17-22) after diagnosis. The prevalence of mild left ventricular systolic dysfunction was 10.4% among breast cancer survivors, versus 3.5% of controls (OR 3.1, 95% CI 1.2-8.1). Mixed-effects modeling showed that LVEF slightly improved over time across groups, without interactions between timepoint and group. CONCLUSION AND DISCUSSION: Long-term breast cancer survivors who received chemotherapy with/without radiation therapy are at increased risk of mild left ventricular systolic dysfunction compared to controls. Despite this elevated risk, left ventricular function slightly improved for all women over time and remained clinically irrelevant.

Indexed as

Breast NeoplasmsCancer SurvivorsVentricular Dysfunction, LeftVentricular Dysfunction, RightAgedAntineoplastic Combined Chemotherapy ProtocolsCase-Control StudiesChemoradiotherapyEchocardiographyFemaleFollow-Up StudiesHumansLongitudinal StudiesMiddle AgedPrevalenceStroke VolumeBreast cancerEchocardiographyGeneral practitionerLeft ventricular systolic dysfunctionLong-term adverse effectsSurvivors

Identifiers

PMID41962383
PMCPMC13091831

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.